Korro Bio Inc
NASDAQ:KRRO

Watchlist Manager
Korro Bio Inc Logo
Korro Bio Inc
NASDAQ:KRRO
Watchlist
Price: 10.34 USD -3.63% Market Closed
Market Cap: $97.4m

Net Margin

-1 199.5%
Current
Improving
by 837.3%
vs 3-y average of -2 036.9%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1 199.5%
=
Net Income
$-88.4m
/
Revenue
$7.4m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1 199.5%
=
Net Income
$-88.4m
/
Revenue
$7.4m

Peer Comparison

Country Company Market Cap Net
Margin
US
Korro Bio Inc
NASDAQ:KRRO
97.2m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
389.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.3B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
170.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.4B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.4B USD
Loading...

Market Distribution

Lower than 94% of companies in the United States of America
Percentile
6th
Based on 15 072 companies
6th percentile
-1 199.5%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Korro Bio Inc
Glance View

Market Cap
97.4m USD
Industry
Biotechnology

Korro Bio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts and currently employs 48 full-time employees. The company went IPO on 2019-10-03. Korro Bio, Inc. is a biopharmaceutical company. The firm discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The firm is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. OPERA co-opts the cell’s natural process with its synthetic oligo and catalyzes a single base change to modify protein sequence and function without the need to permanently modify one’s genome. The firm's focus areas include the liver and central nervous system (CNS).

KRRO Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-1 199.5%
=
Net Income
$-88.4m
/
Revenue
$7.4m
What is Korro Bio Inc's current Net Margin?

The current Net Margin for Korro Bio Inc is -1 199.5%, which is above its 3-year median of -2 036.9%.

How has Net Margin changed over time?

Over the last 8 months, Korro Bio Inc’s Net Margin has increased from -3 680.4% to -1 199.5%. During this period, it reached a low of -3 680.4% on Dec 31, 2024 and a high of -1 199.5% on Sep 30, 2025.

Back to Top